1. Pink Sheet
  2. >>Geography
  3. >>Europe

ABPI Presents Pre-Election Vision For Boosting UK Clinical Trials, Innovation & Manufacturing

 
• By Francesca Bruce

The ABPI’s “manifesto for investment, health and growth” says that the new government to be elected later this year must ensure that investment in new medicines and research accelerates future innovation and attracts more R&D to the UK.

Changes ahead sign against blue sky. 3D illustration. - Illustration
The UK ABPI is looking for changes to life sciences policy from a future government • Source: Shutterstock

Shortly after the UK Labour Party disclosed its plans for boosting the country’s life sciences sector, the Association of the British Pharmaceutical Industry published its own proposals outlining what a new government must do to “make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.”

With a general election expected sometime in the second half of this year, the ABPI has welcomed Labour’s life science plan, saying it would “help our industry to deliver the cutting-edge treatments National Health Service patients need and deserve and help the UK to better compete on the global stage

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

More from Geography

Darzalex Faspro Gains US FDA AdComm Support For Smoldering Myeloma Claim

 
• By Bridget Silverman

The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.

STARGLO Dulled: Genentech’s Columvi Data Not Generalizable To US Patients, FDA Panel Says

 
• By Sue Sutter

The glofitamab trial results are not generalizable due to the small number of enrolled US lymphoma patients and adverse results across multiple endpoints for patients from non-Asian regions, the Oncologic Drugs Advisory Committee said.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.